Description

Val-Ala-PABC-Exatecan trifluoroacetate is a Drug-Linker Conjugates for ADC, consiting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (topoisomerase I inhibitor, HY-13631). Val-Ala-PABC-Exatecan trifluoroacetate can be used for ADC molecues synthesis, such as Mal-PEGn-amide-va-Exatecan[1].-4°C (Powder, sealed storage, away from moisture and light)-Applications-Cancer-programmed cell death-Formula-C42H44F4N6O10-Citation–References-[1]Cheng X, et al. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Mol Cancer Ther. 2018 Dec;17(12):2665-2675.-CASNumber-2928571-45-1-MolecularWeight-868.83-Compound Purity-98.39-SMILES-CC[C@]1(C(OCC2=C1C=C3C4=NC5=CC(F)=C(C6=C5C([C@H](CC6)NC(OCC7=CC=C(C=C7)NC([C@@H](NC([C@H](C(C)C)N)=O)C)=O)=O)=C4CN3C2=O)C)=O)O.OC(C(F)(F)F)=O-Research_Area-Cancer-Solubility-DMSO : 50 mg/mL (ultrasonic)-Target-Drug-Linker Conjugates for ADC;Topoisomerase-Isoform-Camptothecins-Pathway-Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage-MCE Product type-ADC Related